A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

Trial Details

NCT ID
NCT05651932
Phase
PHASE1
Sponsor
K36 Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Cohort A1 & A2: KTX-1001
  • Cohort B1 & B2: KTX-1001+Mezigdomide
  • Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
  • Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • ≥ 18 years of age
  • ECOG score ≤ 1
  • Multiple myeloma (as per IMWG)
  • Prior therapy for MM: Participants must have received at least 1 and up to 3 prior lines of therapy as defined by IMWG, and the following drug clas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →